Medivir’s Annual Report for 2017 is published

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2017 now is available at the company’s website: www.medivir.com   In 2017, Medivir could present groundbreaking results from the company's first phase IIa study with MIV-711 for the treatment of osteoarthritis. In oncology, Medivir's focus area, strong phase II data were presented for remetinostat against Cutaneous T-cell Lymphoma. Furthermore, during the year a phase I/II study with birinapant was initiated in combination with Merck's Keytruda® for the treatment of advanced solid tumors.